About Us
Company History
The Team
Executive Management
Board of Directors
Scientific Advisory Board
Partners
|
Product
|
Science
Scientific Overview
Epitope-based Approach
Scientific Publications
|
Influenza
The Flu Virus
The Flu and Global Health
Useful Links
|
News & Media
Press Releases
Events & Presentations
BiondVax in the News
Press Kit
|
Investor Relations
Stock Information
Ownership Structure
Financial Reports
Regulatory Filings
|
Careers
|
Contact Us
Home
>> News & Media
News & Media
News & Media
►
Press Releases and
Company News
Events and
Presentations
BiondVax in the News
Press Kit
Press Releases & Company News
2010
8 March 2010
BiondVax Reports Positive Interim Safety Results from Second Phase I/II Universal Influenza Vaccine Trial
English
24 February 2010
BiondVax enters into Term Sheet to secure up to $ 7 Million through a 3 year Standby Equity Distribution Agreement (SEDA) with Yorkville Advisors
English
2009
9 December 2009
Successful Stock Offering
English
7 December 2009
Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals’ Universal Flu Vaccine
English
4 October 2009
Wayne Rudolph Appointed Vice President of Corporate Development at BiondVax
English
7 September 2009
BiondVax will Begin an Additional Clinical Trial: will Examine the Safety of the Universal Flu Vaccine for the Elderly Population
English
25 August 2009
Antibodies for the Swine Flu Virus were Found in the Blood of Mice Injected with BiondVax's Universal Vaccine
English
3 August 2009
Successful Safety Data for BiondVax Even at the Highest Dose of the Universal Flu Vaccine
English
19 July 2009
Success in the Safety Data of 24 Participants in BiondVax's Clinical Trial for a Universal Flu Vaccine; Proceeds to Injection at the Highest Dose
English
5 July 2009
Successful Safety Results in the First Participant Group in BiondVax's Clinical Trial for a Universal Flu Vaccine; the Clinical Trial will be Expanded
English
